New Zealand markets closed

Biodexa Pharmaceuticals Plc (BDRX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0800+0.0500 (+4.85%)
At close: 04:00PM EDT
1.0500 -0.03 (-2.78%)
Pre-market: 07:12AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0300
Open1.0200
Bid1.0600 x 300
Ask1.0900 x 400
Day's range1.0100 - 1.1100
52-week range0.6700 - 9.7400
Volume490,640
Avg. volume5,213,867
Market cap6.043M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)-10.5700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
  • GlobeNewswire

    Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

    May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from

  • GlobeNewswire

    Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

    May 21, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting Overall 83% non-progression rate at 6 Months Statistically Significant decrease in overall mean polyp burden at 6 months (p=0.04) Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage

  • GlobeNewswire

    Posting of Annual Report & Notice of AGM - Total Voting Rights

    May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that its Notice of Annual General Meeting (“AGM”) was posted to shareholders yesterday, along with the Annual Report for the year ended 31 December 2023. The document is a